Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy

由于 MnSOD 生物学的破坏,谱系可塑性驱动了对电离辐射/雄激素剥夺疗法的抵抗

基本信息

  • 批准号:
    10737810
  • 负责人:
  • 金额:
    $ 6.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-09 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

SUMMARY The overarching goal of this new R01 application is to investigate the dysregulation of mitochondrial networks responsible for maintaining normal metabolism is an established hallmark of cancer. This disruption of cellular metabolism, leads to the aberrant accumulation of reactive oxygen species (ROS), triggering maladaptive signaling that is an emerging, novel mechanism leading to ionizing radiation (IR) resistance (IRR) as well as enzalutamide (ENZ) resistance (ENZR). In this regard, recently identified a mitochondrial signaling axis centered on manganese superoxide dismutase (MnSOD) which, when the acetylation (Ac) status of lysine 68 (K68-Ac) is altered, disrupts cellular metabolism, leading to aberrant ROS levels (Zhu, Nature Commun., 2019). In addition, LNCaP cells expressing a MnSOD K68-Ac mimic mutant (MnSODK68Q) exhibited IRR/ENZR, increased HIF2α, known to promote stemness properties, and two stem cell markers, Oct4 and SOX2. As such, we seek to show that MnSOD-K68-Ac may drive IRR and/or ENZR, by altering MnSOD's structural composition and enzymatic activity, and in a broader context, tumor growth and survival via a cell stemness-like mechanism. Finally, will GC4419 exposure, a chemical agent that acts as a MnSOD mimic, reverse the IRR/ENZR phenotype? Thus, it is It is hypothesized that prostate tumor cells exposed to IRR and/or ENZR increase MnSOD-K68-Ac, disrupting normal MnSOD biology at the cellular and mitochondrial level (i.e., aberrant ROS), which initiates cellular reprogramming, via increased HIF2α, leading to lineage plasticity properties, a change in tumor cell fate, and an IRR and/or ENZR tumor phenotype. It is also proposed that MnSOD-K68-Ac is a novel axis for new therapeutic interventions in IRR and IRR/ENZR tumors. Finally, through exposure to GC4419 that chemically replaces MnSOD activity, we ask whether superoxide detoxification reverts/converts these IRR/ENZR prostate tumor cells to a sensitive phenotype by restoring normal metabolism
摘要 这一新的R01应用程序的首要目标是研究线粒体网络的失调 负责维持正常新陈代谢是癌症的既定标志。这种对细胞的破坏 新陈代谢,导致活性氧物种(ROS)的异常积累,引发适应不良 信号是一种导致电离辐射(IR)抵抗(IRR)以及 苯扎鲁胺(ENZ)耐药性(ENZR)。在这方面,最近发现了一个以线粒体信号轴为中心的 关于赖氨酸68(K68-Ac)乙酰化(Ac)状态的锰超氧化物歧化酶(MnSOD) 改变,扰乱细胞新陈代谢,导致ROS水平异常(朱,自然通讯,2019)。此外, 表达MnSODK68-Ac模拟突变体(MnSODK68Q)的LNCaP细胞表现出IRR/ENZR,HIF2α增加, 已知可以促进茎的特性,以及两个干细胞标记,Oct4和SOX2。因此,我们试图展示 MnSOD-K68-Ac可能通过改变MnSOD的结构组成和酶活性来驱动IRR和/或ENZR 在更广泛的背景下,通过细胞干细胞样机制,肿瘤的生长和存活。最后,威尔 GC4419暴露,一种模拟MnSOD的化学试剂,是否逆转IRR/ENZR表型?因此,它 是否假设暴露于IRR和/或ENZR的前列腺肿瘤细胞增加MnSOD-K68-Ac,破坏 在细胞和线粒体水平上的正常MnSOD生物学(即,异常的ROS),它启动了细胞 通过增加HIF2α重新编程,导致谱系可塑性特性,改变肿瘤细胞命运,以及 IRR和/或ENZR肿瘤表型。还提出了MnSOD-K68-Ac是一种新的治疗方法 对IRR和IRR/ENZR肿瘤的干预。最后,通过接触GC4419,化学上取代了 MnSOD活性,我们询问超氧化物歧化是否能逆转/转化这些IRR/ENZR前列腺癌细胞 通过恢复正常新陈代谢转变为敏感的表型

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Gius其他文献

David Gius的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Gius', 18)}}的其他基金

Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
由于 MnSOD 生物学的破坏,谱系可塑性驱动了对电离辐射/雄激素剥夺疗法的抵抗
  • 批准号:
    10533472
  • 财政年份:
    2021
  • 资助金额:
    $ 6.81万
  • 项目类别:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
由于 MnSOD 生物学的破坏,谱系可塑性驱动了对电离辐射/雄激素剥夺疗法的抵抗
  • 批准号:
    10390451
  • 财政年份:
    2021
  • 资助金额:
    $ 6.81万
  • 项目类别:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies
MnSOD-K68-Ac 重新编程 ER 乳腺恶性肿瘤中的谱系可塑性开关/干性
  • 批准号:
    10327336
  • 财政年份:
    2021
  • 资助金额:
    $ 6.81万
  • 项目类别:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies.
MnSOD-K68-Ac 重新编程 ER 乳腺恶性肿瘤中的谱系可塑性开关/干性。
  • 批准号:
    10817556
  • 财政年份:
    2021
  • 资助金额:
    $ 6.81万
  • 项目类别:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
MnSOD-Ac-ROS-HIF2a 轴的失调促进 IR/顺铂耐药表型
  • 批准号:
    10335424
  • 财政年份:
    2021
  • 资助金额:
    $ 6.81万
  • 项目类别:
MnSOD-K68-Ac reprograms a lineage plasticity switch / stemness in ER+ breast malignancies
MnSOD-K68-Ac 重新编程 ER 乳腺恶性肿瘤中的谱系可塑性开关/干性
  • 批准号:
    10541193
  • 财政年份:
    2021
  • 资助金额:
    $ 6.81万
  • 项目类别:
Lineage Plasticity, due to Disruption of MnSOD Biology, drives resistance to Ionizing Radiation / Androgen Deprivation Therapy
由于 MnSOD 生物学的破坏,谱系可塑性驱动了对电离辐射/雄激素剥夺疗法的抵抗
  • 批准号:
    10548835
  • 财政年份:
    2021
  • 资助金额:
    $ 6.81万
  • 项目类别:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
MnSOD-Ac-ROS-HIF2a 轴的失调促进 IR/顺铂耐药表型
  • 批准号:
    10024964
  • 财政年份:
    2017
  • 资助金额:
    $ 6.81万
  • 项目类别:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
MnSOD-Ac-ROS-HIF2a 轴的失调促进 IR/顺铂耐药表型
  • 批准号:
    9889066
  • 财政年份:
    2017
  • 资助金额:
    $ 6.81万
  • 项目类别:
Dys-regulation of the MnSOD-Ac-ROS-HIF2a axis promotes IR / Cisplatin resistance phenotype
MnSOD-Ac-ROS-HIF2a 轴的失调促进 IR/顺铂耐药表型
  • 批准号:
    9262705
  • 财政年份:
    2017
  • 资助金额:
    $ 6.81万
  • 项目类别:

相似海外基金

Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
  • 批准号:
    26462277
  • 财政年份:
    2014
  • 资助金额:
    $ 6.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
  • 批准号:
    8344380
  • 财政年份:
    2012
  • 资助金额:
    $ 6.81万
  • 项目类别:
Allografting for Lukemia
白血病同种异体移植
  • 批准号:
    8260361
  • 财政年份:
    2011
  • 资助金额:
    $ 6.81万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7878675
  • 财政年份:
    2009
  • 资助金额:
    $ 6.81万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7677758
  • 财政年份:
    2009
  • 资助金额:
    $ 6.81万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7466112
  • 财政年份:
    2008
  • 资助金额:
    $ 6.81万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8010394
  • 财政年份:
    2008
  • 资助金额:
    $ 6.81万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8208131
  • 财政年份:
    2008
  • 资助金额:
    $ 6.81万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7575273
  • 财政年份:
    2008
  • 资助金额:
    $ 6.81万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7765518
  • 财政年份:
    2008
  • 资助金额:
    $ 6.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了